Abstract
H2 relaxin (relaxin) is a member of the insulin–relaxin superfamily and exhibits several non-reproductive functions in addition to its well-known properties as a pregnancy hormone. Over the years, the therapeutic potential of relaxin has been examined for a number of conditions. It is currently in phase III clinical trials for the treatment of acute heart failure. The 53 amino acid peptide hormone consists of two polypeptide chains (A and B) which are cross-linked by two inter-chains and one intra-A chain disulfide bridge. Although its cognate receptor is relaxin family peptide receptor (RXFP) 1, relaxin is also able to cross-react with RXFP2, for which the native ligand is INSL3. The “RXXXRXXI” motif in the B-chain of H2 relaxin is responsible for primary binding to LRR of the RXFP1 receptor (Büllesbach and Schwabe, J Biol Chem 280:14051–14056, 2005). Previous RXFP2 receptor mutation and molecular modelling studies strongly suggest that, in addition to this motif, the Trp-B28 residue in the B-chain is responsible for H2–RXFP2 interaction. To confirm this finding, here we have mutated H2 relaxin in which Trp-B28 was replaced with alanine. The synthetic relaxin analogue was then tested on cells expressing either RXFP1 or 2 to determine the affinity and potency for the respective receptors. Our results confirm that Trp-B28 in the B-chain is crucial for binding and activating RXFP2, but not for RXFP1.
Similar content being viewed by others
References
Bathgate RA, Ivell R, Sanborn BM, Sherwood OD, Summers RJ (2006) International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 58:7–31
Büllesbach EE, Schwabe C (1999) Tryptophan B27 in the relaxin-like factor (RLF) is crucial for RLF receptor-binding. Biochemistry 38:3073–3078
Büllesbach EE, Schwabe C (2000) The relaxin receptor-binding site geometry suggests a novel gripping mode of interaction. J Biol Chem 275:35276–35280
Büllesbach EE, Schwabe C (2005) The trap-like relaxin-binding site of the leucine-rich G-protein-coupled receptor 7. J Biol Chem 280:14051–14056
Büllesbach EE, Yang S, Schwabe C (1992) The receptor-binding site of human relaxin II. A dual prong-binding mechanism. J Biol Chem 267:22957–22960
Chan LJ, Hossain MA, Samuel CS, Separovic F, Wade JD (2011) The relaxin peptide family: structure, function and clinical applications. Protein Pept Lett 18:220–229
Eigenbrot C, Randal M, Quan C et al (1991) X-ray structure of human relaxin at 1.5 A. Comparison to insulin and implications for receptor binding determinants. J Mol Biol 221:15–21
Halls ML, Bathgate RA, Sudo S et al (2005a) Identification of binding sites with differing affinity and potency for relaxin analogues on LGR7 and LGR8 receptors. Ann N Y Acad Sci 1041:17–21
Halls ML, Bond CP, Sudo S et al (2005b) Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J Pharmacol Exp Ther 313:677–687
Hossain MA, Zhang S, Lin F et al (2006) Regioselective disulfide solid phase synthesis, chemical characterization and in vitro receptor binding activity of equine relaxin. Int J Pept Res Ther 12:211–215
Hossain MA, Bathgate RA, Kong CK et al (2008) Synthesis, conformation, and activity of human insulin-like peptide 5 (INSL5). ChemBioChem 9:1816–1822
Hossain MA, Rosengren KJ, Samuel CS et al (2011) The minimal active structure of human relaxin-2. J Biol Chem 286:37555–37565
Hsu SY, Nakabayashi K, Nishi S et al (2002) Activation of orphan receptors by the hormone relaxin. Science 295:671–674
Kumagai J, Hsu SY, Matsumi H et al (2002) INSL3/Leydig insulin-like peptide activates the LGR8 receptor important in testis descent. J Biol Chem 277:31283–31286
Rosengren KJ, Zhang S, Lin F et al (2006) Solution structure and characterization of the LGR8 receptor binding surface of insulin-like peptide 3. J Biol Chem 281:28287–28295
Scott DJ, Fu P, Shen PJ et al (2005) Characterization of the rat INSL3 receptor. Ann N Y Acad Sci 1041:13–16
Scott DJ, Layfield S, Yan Y et al (2006) Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules. J Biol Chem 281:34942–34954
Scott DJ, Wilkinson TN, Zhang S et al (2007) Defining the LGR8 residues involved in binding insulin-like peptide 3. Mol Endocrinol 21:1699–1712
Scott DJ, Tregear GW, Bathgate RAD (2009) Modeling the primary hormone-binding site of RXFP1 and RXFP2. Ann N Y Acad Sci 1160:74–77
Scott DJ, Rosengren KJ, Bathgate RAD (2012) The different ligand-binding modes of relaxin family peptide receptors RXFP1 and RXFP2. Mol Endocrinol 26 (in press)
Shabanpoor F, Bathgate RA, Belgi A et al (2012) Site-specific conjugation of a lanthanide chelator and its effects on the chemical synthesis and receptor binding affinity of human relaxin-2 hormone. Biochem Biophys Res Commun 420:253–256
Acknowledgments
We thank Tania Ferraro and Sharon Layfield for their assistance with the biochemical assays. This work was supported by an NHMRC Grant (APP #1023078) to JDW, RADB and MAH, and (APP #1023321) to MAH. JDW and RADB are recipients of NHMRC Principal and Senior Research Fellowships, respectively. Studies at the FNI were supported by the Victorian Government’s Operational Infrastructure Support Program.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Chan, L.J., Wade, J.D., Separovic, F. et al. The Importance of Tryptophan B28 in H2 Relaxin for RXFP2 Binding and Activation. Int J Pept Res Ther 19, 55–60 (2013). https://doi.org/10.1007/s10989-012-9332-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-012-9332-x